The role of asenapine in the treatment of manic or mixed states associated with bipolar I disorder

Neuropsychiatric Disease and Treatment

Volumn 7, Issue 1, 2011, Pages 259-265

  Pompili, Maurizio ^a,b   Venturini, Paola ^a   Innamorati, Marco ^a   Serafini, Gianluca ^a   Telesforo, Ludovica ^a   Lester, David ^c   Tatarelli, Roberto ^a   Girardi, Paolo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b HARVARD MEDICAL SCHOOL   (United States)

^c RICHARD STOCKTON COLLEGE OF NEW JERSEY   (United States)

Author keywords

Asenapine; Bipolar disorder; Side effects

Indexed keywords

ASENAPINE; OLANZAPINE; ORG 52222; PLACEBO; UNCLASSIFIED DRUG;

AKATHISIA; ARTICLE; BIPOLAR I DISORDER; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE ASSOCIATION; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPESTHESIA; LABORATORY TEST; MIXED MANIA AND DEPRESSION; NAUSEA; OUTCOME ASSESSMENT; REMISSION; SIDE EFFECT; SOMNOLENCE; VITAL SIGN; WEIGHT GAIN; YOUNG MANIA RATING SCALE;

EID: 80053649664     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S17259     Document Type: Article

References (24)

1. Pompili M, Rihmer Z, Innamorati M, Lester D, Girardi P, Tatarelli R. Assessment and treatment of suicide risk in bipolar disorders. Expert Rev Neurother. 2009;9(1):109-136.
2. Vieta E, Sanchez-Moreno J. Acute and long-term treatment of mania. Dialogues Clin Neurosci. 2008;10(2):165-179.
3. Moller HJ, Demyttenaere K, Sacchetti E, Rush AJ, Montgomery SA. Improving the chance of recovery from the short- and long-term consequences of depression. Int Clin Psychopharmacol. 2003; 18(4): 219-225.
4. Demyttenaere K, Enzlin P, Dewe W, et al. Compliance with antidepressants in a primary care setting, 2: the influence of gender and type of impairment. J Clin Psychiatry. 2001;62(Suppl 22):34-37.
5. Peveler R, George C, Kinmonth AL, Campbell M, Thompson C. Effect of antidepressant drug counselling and information leaflets on adherence to drug treatment in primary care: randomised controlled trial. BMJ. 1999; 319(7210):612-615.
6. Melfi CA, Chawla AJ, Croghan TW, Hanna MP, Kennedy S, Sredl K. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry. 1998;55(12): 1128-1132.
7. Thase ME, Nierenberg AA, B. KM, Panagides J. Efficacy of mirtazapine for prevention of depressive relapse: a placebo controlled double-blind trial of recently remitted high-risk patients. J Clin Psychiatry. 2001; 62(10):782-788.
8. Lingam R, Scott J. Treatment non-adherence in affective disorders. Acta Psychiatr Scand. 2002;105(3):164-172.
9. Muller-Oerlinghausen B, Berghofer A, Ahrens B. The antisuicidal and mortality-reducing effect of lithium prophylaxis: consequences for guidelines in clinical psychiatry. Can J Psychiatry. 2003;48(7): 433-439.
10. Tondo L, Isacsson G, Baldessarini R. Suicidal behaviour in bipolar disorder: risk and prevention. CNS Drugs. 2003;17(7):491-511.
11. Craig TJ, Ye Q, Bromet EJ. Mortality among first-admission patients with psychosis. Compr Psychiatry. 2006;47(4):246-251.
12. Dutta R, Boydell J, Kennedy N, Van Os J, Fearon P, Murray RM. Suicide and other causes of mortality in bipolar disorder: a longitudinal study. Psychol Med. 2007;37(6):839-847.
13. Khalsa HM, Salvatore P, Hennen J, Baethge C, Tohen M, Baldessarini RJ. Suicidal events and accidents in 216 first-episode bipolar I disorder patients: predictive factors. J Affect Disord. 2008;106(1-2):179-184.
14. Meltzer HY, Dritselis A, Yasothan U, Kirkpatrick P. Asenapine. Nat Rev Drug Discov. 2009;8(11):843-844.
15. Hussar DA, Abbas CA. New drugs: asenapine, iloperidone, and bepotastine besilate. J Am Pharm Assoc (2003). 2010;50(1):107-110.
16. Minassian A, Young JW. Evaluation of the clinical efficacy of asenapine in schizophrenia. Expert Opin Pharmacother. 2010;11(12):2107-2115.
17. Citrome L. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. Int J Clin Pract. 2009; 63(12):1762-1784.
18. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord. 2009;11(7):673-686.
19. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study. J Affect Disord. 2010;126(3):358-365.
20. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Affect Disord. 2010;122(1-2):27-38.
21. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine versus olanzapine in acute mania: a double-blind extension study. Bipolar Disord. 2009;11(8):815-826.
22. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133: 429-435.
23. RS. Asenapine: A review of acute and extension phase data in bipolar disorder. CNS Neurosci Ther. 2010 Oct 15. doi: 10.1111/j.1755-5949.2010.00200.x. [Epub ahead of print].
24. Weber J, McCormack PL. Asenapine. CNS Drugs. 2009;23(9): 781-792.